BlackRock
NMRA icon

BlackRock’s Neumora Therapeutics NMRA Stock Holding History

BlackRock’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Buy
7,791,869
+5,737,553
+279% +$10.9M ﹤0.01% 3520
2026
Q1 		$4.01M Buy
2,054,316
+29,372
+1% +$76.1K ﹤0.01% 3915
2025
Q4 		$3.62M Buy
2,024,944
+209,014
+12% +$458K ﹤0.01% 3948
2025
Q3 		$3.3M Sell
1,815,930
-1,066,179
-37% -$1.72M ﹤0.01% 3943
2025
Q2 		$2.11M Sell
2,882,109
-3,472,424
-55% -$2.63M ﹤0.01% 4044
2025
Q1 		$6.35M Sell
6,354,533
-752,463
-11% -$1.29M ﹤0.01% 3539
2024
Q4 		$75.3M Buy
7,106,996
+920,102
+15% +$11M ﹤0.01% 2232
2024
Q3 		$81.7M Buy
6,186,894
+1,583,500
+34% +$18.5M ﹤0.01% 2198
2024
Q2 		$45.3M Buy
4,603,394
+3,617,823
+367% +$37.4M ﹤0.01% 2472
2024
Q1 		$13.6M Sell
985,571
-58,433
-6% -$945K ﹤0.01% 3188
2023
Q4 		$17.8M Buy
1,044,004
+1,019,004
+4,076% +$12.5M ﹤0.01% 3078
2023
Q3 		$353K Buy
+25,000
New +$312K ﹤0.01% 4520

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock's NMRA Position: Q2 2026 in Review

BlackRock increased its Neumora Therapeutics (NMRA) stake by 279% in Q2 2026, buying an estimated $10.9M and bringing the position to 7,791,869 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3520.

BlackRock first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $81.7M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • BlackRock held 7,791,869 shares of Neumora Therapeutics worth $13.2M as of Q2 2026.
  • BlackRock bought 5,737,553 Neumora Therapeutics shares in Q2 2026, an estimated $10.9M.
  • Neumora Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3520 holding.
  • BlackRock first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • BlackRock's Neumora Therapeutics position peaked at $81.7M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.